Recent studies have focused on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopaminergic signaling. While GLP activators are commonly employed for managing type 2 diabetes mellitus, their potential consequences on reinforcement circuits,